US Has Opportunity To Lead On Ophthalmic Biosimilars

Cardinal Health’s Sonia Oskouei Expands On Findings Of 2022 Biosimilars Report

With key milestones on the horizon for US biosimilars in 2022 and 2023, Cardinal Health’s vice president of biosimilars, Sonia Oskouei, explains how the industry can best position itself to take advantage of these upcoming opportunities – including potentially a global leadership role in ophthalmology – in an exclusive interview with Generics Bulletin.

Turning Point Sign
Cardinal Health says 2022 will be a turning point for US biosimilars • Source: YAY Media AS / Alamy Stock Photo

After a gradual ramp-up in the US biosimilars market since the Biologics Price Competition and Innovation Act first created the framework for US biosimilars in 2009, recent years have seen progress accelerate, with several major leaps forward.

Following a boost from a trio of oncology biosimilars – bevacizumab, trastuzumab and rituximab – that were launched by multiple players in 2019 and 2020, last year saw further advances such as the first approved interchangeable and thus substitutable biosimilar, as

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Products